Troponins in acute coronary syndrome

Reading Document

Medical Text Search

troponin biomarker acute coronary syndrome diagnosis

Medical Text Search

high-sensitivity troponin assay NSTEMI STEMI serial testing

GradeResponse

Medical Image Search

troponin rise and fall kinetics ACS myocardial infarction

Medical Text Search

troponin elevation causes non-ischemic cardiac injury false positive

GradeResponse

Troponins in Acute Coronary Syndrome (ACS)

What Are Cardiac Troponins?

Troponins are regulatory proteins of the actin-myosin contractile apparatus. Three isoforms exist: troponin I (cTnI), troponin T (cTnT), and troponin C. Only cTnI and cTnT have cardiac-specific isoforms, making them the preferred biomarkers for myocardial injury. They are released into the bloodstream when cardiomyocyte membrane integrity is disrupted.

Role in ACS Diagnosis

Troponins — alongside ECG and clinical presentation — form the diagnostic triad for ACS. They are the preferred biomarkers for detecting myocardial necrosis (Bailey & Love's, p. 969):

ACS Subtype	Troponin Finding
STEMI	Elevated (diagnosis primarily ECG-based; troponins confirm necrosis)
NSTEMI	Elevated above 99th percentile URL with a rising/falling pattern
Unstable Angina	Normal (no myocardial necrosis)

Troponin Kinetics in Acute MI

The rise-and-fall pattern is the hallmark of acute, ischemic myocardial injury and distinguishes it from chronic myocardial injury (where levels are persistently, stably elevated above the 99th percentile):

Troponin kinetics: acute MI vs. chronic injury

Acute MI shows a sharp rise peaking at later sampling, then decline. Chronic injury remains flat just above the 99th percentile URL. (Diagnosing and Managing ACS, p. 30)

Typical timeline for conventional troponin:

Detectable: ~3–6 hours after symptom onset
Peaks: ~12–24 hours
Normalizes: 5–14 days (cTnI faster; cTnT may persist longer)

High-Sensitivity Troponin (hs-cTn) Assays

hs-cTn assays have transformed ACS workup by detecting troponin elevations earlier and at lower concentrations. The ESC guidelines recommend the 0h/1h or 0h/2h algorithm for rapid rule-out and rule-in of NSTEMI (Management of ACS, p. 22):

Three pathways based on hs-cTn results at 0h and 1h/2h:

Pathway	Criteria	Action
Rule-Out	Very low 0h value, OR low 0h + no significant 1h/2h delta	Discharge / low-risk pathway
Rule-In	High 0h value, OR large 1h/2h delta	NSTEMI confirmed → invasive strategy
Observe	Neither rule-out nor rule-in criteria met	Repeat hs-cTn at 3h ± echo

Key point: Cut-offs are assay-specific and must meet pre-defined sensitivity/specificity thresholds. The 0h/1h algorithm is only applicable if chest pain onset was >3 hours prior to initial measurement.

The 99th Percentile Upper Reference Limit (URL)

Definition: The 99th percentile of hs-cTn in a healthy reference population — this is the diagnostic threshold for myocardial injury.
Elevation above the URL + a rising/falling pattern = acute myocardial injury.
Values above URL without dynamic change = chronic myocardial injury (e.g., heart failure, CKD, LVH).

Causes of Troponin Elevation (Beyond ACS)

Troponin elevation is a marker of myocardial injury, not necessarily ischemia. Other causes include:

Cardiac (non-ACS):

Myocarditis, pericarditis
Heart failure (acute decompensation)
Hypertensive emergency
Takotsubo cardiomyopathy
Arrhythmias (e.g., SVT, AF with rapid ventricular rate)
Cardiac contusion
Post-cardioversion

Non-Cardiac:

Pulmonary embolism
Sepsis / critical illness
Stroke, subarachnoid haemorrhage
Renal failure (reduced clearance)
Rhabdomyolysis
Burns, chemotherapy toxicity

Practical Clinical Points

Serial testing is mandatory — a single value is insufficient; the kinetic pattern (rising/falling) is what defines acute MI.
Clinical context is essential — elevated troponin + chest pain + ECG changes = ACS until proven otherwise; elevated troponin alone in a septic patient likely reflects demand ischemia or direct injury.
hs-cTn detects smaller infarcts and elevates earlier, improving sensitivity but reducing specificity — this makes context and delta changes more important.
cTnI vs. cTnT: Both are cardiac-specific. cTnT may remain elevated longer (useful for late presentations); cTnI may clear faster. Assays are not interchangeable.
Gender differences: Women have lower baseline hs-cTnI levels; some guidelines recommend sex-specific cut-offs.

Other Cardiac Biomarkers (Comparison)

Biomarker	Rise	Peak	Normalization	Advantage
hs-cTnI/T	1–3 h	12–24 h	5–14 days	Earliest, most sensitive/specific
CK-MB	3–6 h	12–24 h	48–72 h	Useful for re-infarction detection
Myoglobin	1–3 h	6–9 h	24 h	Early marker, not cardiac-specific
BNP/NT-proBNP	Hours	Variable	Variable	Risk stratification, heart failure

Troponins remain the cornerstone biomarker in ACS. The shift to hs-cTn assays and the ESC 0h/1h/2h algorithms has enabled faster, more accurate triage — but clinical judgment integrating symptoms, ECG, and serial values remains indispensable.

This is a shared conversation. Sign in to Orris to start your own chat.